Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

NCT06107413 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

280

Enrollment

INDUSTRY

Sponsor class

Conditions

Unresectable Metastatic Colorectal Cancer

Interventions

DRUG: ABBV-400
DRUG: Bevacizumab
DRUG: Folinic Acid
DRUG: Fluorouracil
DRUG: Irinotecan

Sponsor

AbbVie